MoonLake Immunotherapeutics(US:MLTX) Globenewswire·2025-10-30 13:09Core Points - A securities fraud class action lawsuit has been filed against MoonLake Immunotherapeutics, alleging violations of the Securities Exchange Act of 1934 [3][4] - The lawsuit claims that the company made misrepresentations regarding its drug candidate, sonelokimab (SLK), which was marketed as superior to competing monoclonal antibody drugs [4] Summary by Sections Lawsuit Details - The lawsuit was initiated on behalf of investors who purchased or acquired MoonLake common stock between March 10, 2024, and September 29, 2025 [3] - Investors are reminded of a deadline to file as lead plaintiff by December 15, 2025, with no fees or expenses required from shareholders [5] Company Background - Bernstein Liebhard LLP, the law firm handling the case, has recovered over $3.5 billion for clients since 1993 and has a strong track record in class action litigation [6]